Novel regimens identified in mice for treatment of latent tuberculosis infection in contacts of patients with multidrug-resistant tuberculosis

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 4, 2014, Pages 2316-2321

  Lanoix, Jean Philippe ^a   Betoudji, Fabrice ^a   Nuermbergera, Eric ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6,7 DIHYDRO 2 NITRO 6 (4 TRIFLUOROMETHOXYBENZYLOXY) 5H IMIDAZO[2,1 B][1,3]OXAZINE; BEDAQUILINE; ISONIAZID; LEVOFLOXACIN; RIFAMPICIN; SUTEZOLID;

AEROSOL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC THERAPY; ARTICLE; BCG VACCINATION; C3HEB/FE MOUSE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; FEMALE; LATENT TUBERCULOSIS; MOUSE; MULTIDRUG RESISTANT TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTITUBERCULAR AGENTS; FEMALE; LATENT TUBERCULOSIS; MICE; MICE, INBRED BALB C; MYCOBACTERIUM BOVIS; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84896938981     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02658-13     Document Type: Article

References (31)

1. World Health Organization. 2013. Global tuberculosis report 2013. World Health Organization, Geneva, Switzerland.
2. Low S, Ang LW, Cutter J, James L, Chee CB, Wang YT, Chew SK. 2009. Mortality among tuberculosis patients on treatment in Singapore. Int. J. Tuberc. Lung Dis. 13:328-334.
3. Kim DH, Kim HJ, Park SK, Kong SJ, Kim YS, Kim TH, Kim EK, Lee KM, Lee SS, Park JS, Koh WJ, Lee CH, Shim TS. 2010. Treatment outcomes and survival based on drug resistance patterns in multidrug-resistant tuberculosis. Am. J. Respir. Crit. Care Med. 182:113-119. http://dx.doi.org/10.1164/rccm.200911-1656OC.
4. Becerra MC, Appleton SC, Franke MF, Chalco K, Arteaga F, Bayona J, Murray M, Atwood SS, Mitnick CD. 2011. Tuberculosis burden in households of patients with multidrug-resistant and extensively drug-resistant tuberculosis: a retrospective cohort study. Lancet 377:147-152. http://dx.doi.org/10.1016/S0140- 6736(10)61972-1.
5. World Health Organization. 2011. Guidelines for the programmatic management of drug-resistant tuberculosis - 2011 update. World Health Organization, Geneva, Switzerland.
6. van der Werf MJ, Langendam MW, Sandgren A, Manissero D. 2012. Lack of evidence to support policy development for management of contacts of multidrug-resistant tuberculosis patients: two systematic reviews. Int. J. Tuberc. Lung Dis. 16:288-296. http://dx.doi.org/10.5588/ijtld.11.0437.
7. Anonymous. 2000. Targeted tuberculin testing and treatment of latent tuberculosis infection. Am. J. Respir. Crit. Care Med. 161:S221-S247. http://dx.doi.org/10.1164/ajrccm.161.supplement-3.ats600.
8. Lanoix JP, Nuermberger E. 2013. Sutezolid. Oxazolidinone antibacterial, treatment of tuberculosis. Drugs Future 38:387-394. http://dx.doi.org/10.1358/ dof.2013.38.6.1965098.
9. Tasneen R, Li SY, Peloquin CA, Taylor D, Williams KN, Andries K, Mdluli KE, Nuermberger EL. 2011. Sterilizing activity of novel TMC207-and PA-824-containing regimens in a murine model of tuberculosis. Antimicrob. Agents Chemother. 55:5485-5492. http://dx.doi.org/10.1128/AAC.05293-11.
10. Williams K, Minkowski A, Amoabeng O, Peloquin CA, Taylor D, Andries K, Wallis RS, Mdluli KE, Nuermberger EL. 2012. Sterilizing activities of novel combinations lacking first- and second-line drugs in a murine model of tuberculosis. Antimicrob. Agents Chemother. 56:3114-3120. http://dx.doi.org/10. 1128/AAC.00384-12.
11. Nuermberger E, Tyagi S, Williams KN, Rosenthal I, Bishai WR, Grosset JH. 2005. Rifapentine, moxifloxacin, or DNA vaccine improves treatment of latent tuberculosis in a mouse model. Am. J. Respir. Crit. Care Med. 172:1452-1456. http://dx.doi.org/10.1164/rccm.200507-1047OC. (Pubitemid 43069820)
12. Diacon AH, Dawson R, Hanekom M, Narunsky K, Maritz SJ, Venter A, Donald PR, van Niekerk C, Whitney K, Rouse DJ, Laurenzi MW, Ginsberg AM, Spigelman MK. 2010. Early bactericidal activity and pharmacokinetics of PA-824 in smear-positive tuberculosis patients. Antimicrob. Agents Chemother. 54:3402-3407. http://dx.doi.org/10.1128/AAC.01354-09.
13. Diacon AH, Dawson R, du Bois J, Narunsky K, Venter A, Donald PR, van Niekerk C, Erondu N, Ginsberg AM, Becker P, Spigelman MK. 2012. Phase II dose-ranging trial of the early bactericidal activity of PA-824. Antimicrob. Agents Chemother. 56:3027-3031. http://dx.doi.org/10.1128/AAC.06125-11.
14. Diacon AH, Pym A, Grobusch M, Patientia R, Rustomjee R, Page-Shipp L, Pistorius C, Krause R, Bogoshi M, Churchyard G, Venter A, Allen J, Palomino JC, De Marez T, van Heeswijk RP, Lounis N, Meyvisch P, Verbeeck J, Parys W, de Beule K, Andries K, Mc Neeley DF. 2009. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N. Engl. J. Med. 360:2397-2405. http://dx.doi.org/10.1056/NEJMoa0808427.
15. Zhang T, Zhang M, Rosenthal IM, Grosset JH, Nuermberger EL. 2009. Short-course therapy with daily rifapentine in a murine model of latent tuberculosis infection. Am. J. Respir. Crit. Care Med. 180:1151-1157. http://dx.doi.org/10.1164/rccm.200905-0795OC.
16. Zhang T, Li SY, Williams KN, Andries K, Nuermberger EL. 2011. Short-course chemotherapy with TMC207 and rifapentine in a murine model of latent tuberculosis infection. Am. J. Respir. Crit. Care Med. 184:732-737. http://dx.doi.org/10.1164/rccm.201103-0397OC.
17. Shandil RK, Jayaram R, Kaur P, Gaonkar S, Suresh BL, Mahesh BN, Jayashree R, Nandi V, Bharath S, Balasubramanian V. 2007. Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy. Antimicrob. Agents Chemother. 51:576-582. http://dx.doi.org/10.1128/AAC.00414- 06. (Pubitemid 46185275)
18. Ahmad Z, Tyagi S, Minkowski A, Peloquin CA, Grosset JH, Nuermberger EL. 2013. Contribution of moxifloxacin or levofloxacin in secondline regimens with or without continuation of pyrazinamide in murine tuberculosis. Am. J. Respir. Crit. Care Med. 188:97-102. http://dx.doi.org/10.1164/rccm.201212-2328OC.
19. Nuermberger EL, Yoshimatsu T, Tyagi S, Bishai WR, Grosset JH. 2004. Paucibacillary tuberculosis in mice after prior aerosol immunization with Mycobacterium bovis BCG. Infect. Immun. 72:1065-1071. http://dx.doi.org/10.1128/ IAI.72.2.1065-1071.2004. (Pubitemid 38166689)
20. Tufariello JM, Chan J, Flynn JL. 2003. Latent tuberculosis: mechanisms of host and bacillus that contribute to persistent infection. Lancet Infect. Dis. 3:578-590. http://dx.doi.org/10.1016/S1473-3099(03)00741-2. (Pubitemid 37064537)
21. Barry CE, Boshoff HI, Dartois V, Dick T, Ehrt S, Flynn J, Schnappinger D, Wilkinson RJ, Young D. 2009. The spectrum of latent tuberculosis: rethinking the biology and intervention strategies. Nat. Rev. Microbiol. 7:845-855. http://dx.doi.org/10.1038/nrmicro2236.
22. Kramnik I, Demant P, Bloom BB. 1998. Susceptibility to tuberculosis as a complex genetic trait: analysis using recombinant congenic strains of mice. Novartis Found. Symp. 217:120-131; discussion 132-127. http://dx.doi.org/10. 1002/0470846526.ch9.
23. Driver ER, Ryan GJ, Hoff DR, Irwin SM, Basaraba RJ, Kramnik I, Lenaerts AJ. 2012. Evaluation of a mouse model of necrotic granuloma formation using C3HeB/FeJ mice for testing of drugs against Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 56:3181-3195. http://dx.doi.org/10.1128/AAC.00217- 12.
24. Pichugin AV, Yan BS, Sloutsky A, Kobzik L, Kramnik I. 2009. Dominant role of the sst1 locus in pathogenesis of necrotizing lung granulomas during chronic tuberculosis infection and reactivation in genetically resistant hosts. Am. J. Pathol. 174:2190-2201. http://dx.doi.org/10.2353/ajpath.2009.081075.
25. Harper J, Skerry C, Davis SL, Tasneen R, Weir M, Kramnik I, Bishai WR, Pomper MG, Nuermberger EL, Jain SK. 2012. Mouse model of necrotic tuberculosis granulomas develops hypoxic lesions. J. Infect. Dis. 205:595-602. http://dx.doi.org/10.1093/infdis/jir786.
26. Rosenthal IM, Tasneen R, Peloquin CA, Zhang M, Almeida D, Mdluli KE, Karakousis PC, Grosset JH, Nuermberger EL. 2012. Dose-ranging comparison of rifampin and rifapentine in two pathologically distinct murine models of tuberculosis. Antimicrob. Agents Chemother. 56:4331-4340. http://dx.doi.org/10. 1128/AAC.00912-12.
27. Williams KN, Stover CK, Zhu T, Tasneen R, Tyagi S, Grosset JH, Nuermberger E. 2009. Promising antituberculosis activity of the oxazolidinone PNU-100480 relative to that of linezolid in a murine model. Antimicrob. Agents Chemother. 53:1314-1319. http://dx.doi.org/10.1128/AAC.01182-08.
28. Ahmad Z, Peloquin CA, Singh RP, Derendorf H, Tyagi S, Ginsberg A, Grosset JH, Nuermberger EL. 2011. PA-824 exhibits time-dependent activity in a murine model of tuberculosis. Antimicrob. Agents Chemother. 55:239-245. http://dx.doi.org/10.1128/AAC.00849-10.
29. Lecoeur HF, Truffot-Pernot C, Grosset JH. 1989. Experimental short-course preventive therapy of tuberculosis with rifampin and pyrazinamide. Am. Rev. Respir. Dis. 140:1189-1193. http://dx.doi.org/10.1164/ajrccm/140.5.1189. (Pubitemid 19276194)
30. Diacon AH, Donald PR, Pym A, Grobusch M, Patientia RF, Mahanyele R, Bantubani N, Narasimooloo R, De Marez T, van Heeswijk R, Lounis N, Meyvisch P, Andries K, McNeeley DF. 2012. Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrug-resistant tuberculosis: long-term outcome, tolerability, and effect on emergence of drug resistance. Antimicrob. Agents Chemother. 56:3271-3276. http://dx.doi.org/10.1128/AAC.06126-11.
31. U.S. Food and Drug Administration. 2012. Anti-Infective Drugs Advisory Committee Meeting Briefing Document TMC207 (bedaquiline): treatment of Patients with MDR-TB (NDA 204-384). U.S. Food and Drug Administration, Washington, DC. http://www.fda.gov/downloads/advisoryCommittees/CommitteesMeetingMaterials/ Drugs/Anti-InfectiveDrugsAdvisoryCommittee/UCM329260.pdf.